What is the 13F Pro Quality Score for STOK?

13F Pro ranks Stoke Therapeutics, Inc. (STOK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View STOK's current score at https://13fpro.ai/company/STOK (free sign-up required for the full ranking).

Which hedge funds own the most STOK stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of STOK include BlackRock,, RTW INVESTMENTS,, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/STOK as soon as new 13F filings post.

Where does 13F Pro source STOK data?

All Stoke Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Stoke Therapeutics, Inc. files with the SEC under CIK 1623526. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is STOK in?

Stoke Therapeutics, Inc. (STOK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is STOK research updated on 13F Pro?

STOK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Stoke Therapeutics, Inc.(STOK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1623526 STOK stock profile & AI dashboard →

13F Pro Quality Score

24.9/100

Rank #2,681 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

95.3/100

Profitability

2.7/100

Balance Sheet

3.2/100

Earnings Quality

17.1/100

Free Cash Flow

2.3/100

Institutional Flow

33.1/100

Revenue Scale

4.5/100

Dilution Risk

10.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why STOK Scores 25/100

exact factor attribution · 2026-09-11

STOK's composite is driven by revenue growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.1 pts

95th pct

Institutional flow

-0.8 pts

33th pct

Shareholder dilution

-2.0 pts

10th pct

Earnings growth

-2.3 pts

4th pct

Earnings quality

-3.3 pts

17th pct

Capital efficiency

-4.7 pts

3th pct

Scale

-6.8 pts

5th pct

Profitability

-7.1 pts

3th pct

Free cash flow

-7.2 pts

2th pct

Latest change (2026-08-03): 53 → 26 · ↓ Profit margin 56→3; ↓ Free cash flow 58→3

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in STOK

Events flagged as statistical outliers against STOK's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-03
STOK quality score dropped 27 points (53→26) on a new filing
View source filing →

STOK Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Stoke Therapeutics, Inc. (STOK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STOK at 24.9/100 on a 32-signal composite quality model, placing it at rank #2,681 of 2,962 stocks — the bottom half of the AI-ranked universe. STOK scores in the top quartile across revenue growth (95.3). Areas of concern include free cash flow (2.3) and profitability (2.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Stoke Therapeutics, Inc. reports quarterly revenue of $9.3M, net income of $-61.6M, free cash flow of $-58.6M. Top institutional holders of STOK by reported 13-F value include BlackRock, RTW INVESTMENTS, FMR, based on the most recent SEC filings. STOK trades on the Nasdaq exchange and files with the SEC under CIK 1623526. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STOK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Stoke Therapeutics, Inc. directly from SEC EDGAR. Stoke Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 7 and 72 since 2023, currently 24.9 — an improving long-term trajectory across 60 quarterly and live scoring snapshots.

✦

Fun facts about Stoke Therapeutics, Inc.

Quirks, history, and lore behind STOK — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Massachusetts · focused on rare genetic diseases.
2
The Numbers
A small-cap biotech with no approved products yet, meaning revenue is minimal and the company runs on cash from financings rather than product sales.
3
The History
Founded around 2014, the company was built around a novel scientific insight into how cells process genetic instructions — specifically, the idea that you can fix a broken gene by unlocking extra copies the body already hides.
4
The Secret
Its entire platform is built on a concept called RNA upregulation — instead of silencing bad genes (the crowded approach), it coaxes cells to produce more of the right protein from a naturally suppressed backup copy.
5
The Lore
Its lead program targets Dravet syndrome, a catastrophic childhood epilepsy, with a drug designed to boost output from the one good copy of the SCN1A gene patients still carry.
6
The Giveaway
The company's name is literally a verb — to stoke — because its whole mission is stoking gene expression upward, and its ticker on Nasdaq matches that action perfectly.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$9.3M

Net Income

Q2 2026

$-61.6M

Free Cash Flow

Q2 2026

$-58.6M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+404.5% YoY

$184.4MFY 2025

FY22 $12.4MFY23 $8.8MFY24 $36.6MFY25 $184.4M

Net Income

+92.3% YoY

$-6.9MFY 2025

FY22 $-101.1MFY23 $-104.7MFY24 $-89.0MFY25 $-6.9M

Operating Income

+79.7% YoY

$-20.6MFY 2025

FY22 $-104.4MFY23 $-114.8MFY24 $-101.4MFY25 $-20.6M

EPS (Diluted)

+92.7% YoY

$-0.12FY 2025

FY22 $-2.60FY23 $-2.38FY24 $-1.65FY25 $-0.12

Total Assets

+54.1% YoY

$418.4MFY 2025

FY22 $256.1MFY23 $228.3MFY24 $271.6MFY25 $418.4M

Op. Cash Flow

+152.5% YoY

$45.6MFY 2025

FY22 $-31.9MFY23 $-81.1MFY24 $-86.9MFY25 $45.6M

Free Cash Flow

+151.6% YoY

$44.9MFY 2025

FY22 $-35.8MFY23 $-82.7MFY24 $-87.1MFY25 $44.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$184.4M +404.5%	$36.6M +316.3%	$8.8M -29.2%	$12.4M	—	—
Net Income	$-6.9M +92.3%	$-89.0M +15.0%	$-104.7M -3.6%	$-101.1M -17.8%	$-85.8M -64.2%	$-52.2M
Operating Income	$-20.6M +79.7%	$-101.4M +11.7%	$-114.8M -10.0%	$-104.4M -21.3%	$-86.1M -62.3%	$-53.0M
EPS (Diluted)	$-0.12 +92.7%	$-1.65 +30.7%	$-2.38 +8.5%	$-2.60 -11.1%	$-2.34	—
Total Assets	$418.4M +54.1%	$271.6M +18.9%	$228.3M -10.8%	$256.1M +7.2%	$238.9M -19.8%	$297.9M
Operating Cash Flow	$45.6M +152.5%	$-86.9M -7.1%	$-81.1M -154.4%	$-31.9M +52.4%	$-66.9M -58.5%	$-42.2M
Free Cash Flow	$44.9M +151.6%	$-87.1M -5.3%	$-82.7M -130.8%	$-35.8M +47.4%	$-68.1M -57.4%	$-43.3M

Get alerted when STOK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Stoke Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of STOK

BlackRock, Inc.
$192.3M5,877,357 sh
RTW INVESTMENTS, LP
$184.0M5,623,525 sh
FMR LLC
$173.8M5,313,100 sh
Lynx1 Capital Management LP
$132.1M4,038,404 sh
Redmile Group, LLC
$129.1M3,945,920 sh
WELLINGTON MANAGEMENT GROUP LLP
$115.2M3,519,301 sh
MORGAN STANLEY
$113.0M3,452,795 sh
BAKER BROS. ADVISORS LP
$109.2M3,336,697 sh
TORONTO DOMINION BANK
$103.8M3,173,258 sh
STATE STREET CORP
$93.3M2,852,240 sh

Fund	Value	Shares
BlackRock, Inc.	$192.3M	5,877,357
RTW INVESTMENTS, LP	$184.0M	5,623,525
FMR LLC	$173.8M	5,313,100
Lynx1 Capital Management LP	$132.1M	4,038,404
Redmile Group, LLC	$129.1M	3,945,920
WELLINGTON MANAGEMENT GROUP LLP	$115.2M	3,519,301
MORGAN STANLEY	$113.0M	3,452,795
BAKER BROS. ADVISORS LP	$109.2M	3,336,697
TORONTO DOMINION BANK	$103.8M	3,173,258
STATE STREET CORP	$93.3M	2,852,240

Companies Similar to STOK

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ZYME

Zymeworks Inc.

AI score

Very similar · 13 shared holders

BVF INC/IL EcoR1 Capital, LLC Redmile Group, LLC

XNCR

Xencor Inc

AI score

Very similar · 11 shared holders

RTW INVESTMENTS, LP BVF INC/IL BAKER BROS. ADVISORS LP

NRIX

Nurix Therapeutics, Inc.

AI score

Very similar · 13 shared holders

BAKER BROS. ADVISORS LP Redmile Group, LLC Candriam S.C.A.

IDYA

IDEAYA Biosciences, Inc.

AI score

Very similar · 17 shared holders

BAKER BROS. ADVISORS LP DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)Redmile Group, LLC

TSHA

Taysha Gene Therapies, Inc.

AI score

Very similar · 13 shared holders

RTW INVESTMENTS, LP Siren, L.L.C.Polar Capital Holdings Plc

DNTH

Dianthus Therapeutics, Inc. /DE/

AI score

Very similar · 15 shared holders

BAKER BROS. ADVISORS LP T. Rowe Price Investment Management, Inc.DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

VYGR

Voyager Therapeutics, Inc.

AI score

Very similar · 7 shared holders

Opaleye Management Inc.Erste Asset Management GmbH Susquehanna Portfolio Strategies, LLC

GLUE

Monte Rosa Therapeutics, Inc.

AI score

Very similar · 11 shared holders

BAKER BROS. ADVISORS LP BVF INC/IL MPM BioImpact LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put STOK on your watchlist

Track score changes the day Stoke Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is STOK a good stock to buy?

13F Pro's AI-powered analysis of Stoke Therapeutics, Inc. (STOK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STOK are available on the STOK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. STOK is classified as a small company.

Which hedge funds own STOK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STOK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Stoke Therapeutics, Inc.'s investment landscape.